Free Trial

Mineralys Therapeutics Q2 2023 Earnings Report

Mineralys Therapeutics logo
$13.50 +0.39 (+2.97%)
As of 04:00 PM Eastern

Mineralys Therapeutics EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.83
Beat/Miss
Beat by +$0.52
One Year Ago EPS
N/A

Mineralys Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mineralys Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Mineralys Therapeutics Earnings Headlines

“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
See More Mineralys Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mineralys Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mineralys Therapeutics and other key companies, straight to your email.

About Mineralys Therapeutics

Mineralys Therapeutics (NASDAQ:MLYS), a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

View Mineralys Therapeutics Profile

More Earnings Resources from MarketBeat